newsfilter
← Earnings
Earnings Releases·

Lexeo Therapeutics — Third Quarter 2026 Earnings Summary

Lexeo Therapeutics reported positive interim Phase I/II data for its gene therapy candidate LX2020 in patients with PKP2 arrhythmogenic cardiomyopathy, showing an 80% mean reduction in non-sustained ventricular tachycardia and a 44% reduction in premature ventricular contractions in high-dose cohorts. The treatment was generally well tolerated across ten participants, with no clinically significant complement activation observed, prompting the company to design a pivotal study using non-sustained ventricular tachycardia as a primary surrogate endpoint for potential accelerated approval. The U.S. Food and Drug Administration has indicated openness to this endpoint strategy, with the company expecting to initiate the pivotal study in the second half of 2027. Financially, the company reported a net loss of $38.3 million for the third quarter of 2026 and holds $219.1 million in cash and investments, providing an operational runway into 2028.

Company
LEXEO THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology